flurbiprofen has been researched along with Neoplasms in 6 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
"To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil." | 7.79 | Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013) |
"To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil." | 3.79 | Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013) |
"A total of 120 cancer patients was randomly divided into two groups, 60 patients took orally morphine sulfate sustained-release tablets in group A, and another 60 patients receiving the combination treatment of intravenous flurbiprofen axetil and opioid drugs in group B." | 2.79 | Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin. ( Gao, JF; Ou, WL; Rao, ZG; Wang, J; Wang, ZG; Wu, TT; Yang, B; Yao, GQ; Zhang, BC, 2014) |
"Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Anti-inflammatory agents in the management of alimentary mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
"Thirty-seven cases of cancer patients who had bad effect from anaesthetic drugs were received administration of intravenous flurbiprofen axetil with dose of 50 mg/5 ml/day." | 1.35 | Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain. ( Chen, Z; Du, Y; Gu, K; Hao, J; Ning, J; Pan, Y; Sun, G; Wu, H, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lin, R | 1 |
Elf, S | 1 |
Shan, C | 1 |
Kang, HB | 1 |
Ji, Q | 1 |
Zhou, L | 1 |
Hitosugi, T | 1 |
Zhang, L | 1 |
Zhang, S | 1 |
Seo, JH | 1 |
Xie, J | 1 |
Tucker, M | 1 |
Gu, TL | 1 |
Sudderth, J | 1 |
Jiang, L | 1 |
Mitsche, M | 1 |
DeBerardinis, RJ | 1 |
Wu, S | 1 |
Li, Y | 1 |
Mao, H | 1 |
Chen, PR | 1 |
Wang, D | 1 |
Chen, GZ | 1 |
Hurwitz, SJ | 1 |
Lonial, S | 1 |
Arellano, ML | 1 |
Khoury, HJ | 1 |
Khuri, FR | 1 |
Lee, BH | 1 |
Lei, Q | 1 |
Brat, DJ | 1 |
Ye, K | 1 |
Boggon, TJ | 1 |
He, C | 1 |
Kang, S | 1 |
Fan, J | 1 |
Chen, J | 1 |
Şenel, B | 1 |
Öztürk, AA | 1 |
Wu, TT | 1 |
Wang, ZG | 1 |
Ou, WL | 1 |
Wang, J | 1 |
Yao, GQ | 1 |
Yang, B | 1 |
Rao, ZG | 1 |
Gao, JF | 1 |
Zhang, BC | 1 |
Wu, H | 1 |
Chen, Z | 1 |
Sun, G | 1 |
Gu, K | 1 |
Pan, Y | 1 |
Hao, J | 2 |
Du, Y | 1 |
Ning, J | 1 |
Wang, K | 1 |
Shao, Y | 1 |
Cheng, X | 1 |
Yan, Z | 1 |
Lalla, RV | 1 |
Schubert, MM | 1 |
Bensadoun, RJ | 1 |
Keefe, D | 1 |
2 reviews available for flurbiprofen and Neoplasms
Article | Year |
---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Anti-inflammatory agents in the management of alimentary mucositis.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineoplastic Agents; Benzydamin | 2006 |
1 trial available for flurbiprofen and Neoplasms
Article | Year |
---|---|
Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; beta-Endorphin; Drug Synergism; Drug Th | 2014 |
3 other studies available for flurbiprofen and Neoplasms
Article | Year |
---|---|
New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cancer Pain; Cell Line, Tumor; Cell Survival; Chitosan; C | 2019 |
Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain.
Topics: Analgesia; Female; Flurbiprofen; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pain | 2009 |
Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Case-Control Studies | 2013 |